NKGen Biotech, Inc. 8-K

What Happened
NKGen Biotech, Inc. (and subsidiary NKGen Operating Biotech, Inc.) announced on February 20, 2026 that they entered a fourth amendment to their secured promissory note with AlpineBrook Capital GP I Limited. The amendment provides an additional $343,000 (the “Fifth Additional New Loan”), increasing the principal balance of the Note to $27,101,106. The amendment clarifies that interest on this new tranche accrues from February 20, 2026.

Key Details

• Parties: NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. (Borrowers) and AlpineBrook Capital GP I Limited (lender).
• Amendment date: February 20, 2026 (following prior amendments dated Jan 12, Jan 23, and Jan 30, 2026 to the original Jan 5, 2026 Note).
• New funding: $343,000 added; total principal now $27,101,106.
• Interest: Interest on the $343,000 tranche accrues from February 20, 2026.

Why It Matters
This filing documents additional secured financing and an increase in NKGen’s outstanding debt. For investors, the amendment signals continued use of external capital to fund operations, which increases leverage and interest obligations. The specifics—amount added, effective dating of interest, and the secured nature of the note—are material facts investors can use to assess the company’s liquidity position and financing strategy.